糖皮质激素在类风湿关节炎中的应用进展

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (1): 116-120.

• 综述与讲座 • 上一篇

糖皮质激素在类风湿关节炎中的应用进展

李丹丹, 陆进明

皖南医学院弋矶山医院风湿免疫科,芜湖 241000,安徽

收稿日期:2011-10-14 修回日期:2011-12-20 出版日期:2012-01-26 发布日期:2012-02-16
通讯作者: 陆进明,女,主任医师,硕导,类风湿关节炎诊断与治疗。Tel: 13905535989 E-mail: lujm1231@hotmail.com
作者简介:李丹丹,女,在读硕士研究生,类风湿关节炎诊断与治疗。Tel: 15156309639 E-mail: lidandan0625@163.com

Advances of study on glucocorticoids in the treatment of rheumatoid arthritis

LI Dan-dan, LU Jin-ming

Rheumatological Department of Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui, China

Received:2011-10-14 Revised:2011-12-20 Online:2012-01-26 Published:2012-02-16

摘要/Abstract

摘要： 糖皮质激素用于治疗类风湿关节炎已有60余年历史,但由于其不良反应较大,风湿病学家对糖皮质激素在类风湿关节炎治疗中的应用价值一直存在不同的争议。近年来许多临床研究证实,糖皮质激素具有改善病情、抑制骨关节破坏的作用。本文就糖皮质激素在类风湿关节炎治疗中的疗效及不良反应作一综述。

关键词: 类风湿关节炎, 糖皮质激素, 治疗

Abstract: The glucocorticoids treat on patients with rheumatoid arthritis (RA) had a more than sixty years history, due to glucocorticoids have some side effects, different rheumatologists have different opinions. According to some clinical research for the past few years, glucocorticoids can improve the condition and inhibit the damage of join. This article is a review about the clinical effects and side effects of treatment for RA with glucocorticoids

Key words: Rheumatoid arthritis, Glucocorticoids, Treat

中图分类号:

R593.22

李丹丹, 陆进明. 糖皮质激素在类风湿关节炎中的应用进展[J]. 中国临床药理学与治疗学, 2012, 17(1): 116-120.

LI Dan-dan, LU Jin-ming. Advances of study on glucocorticoids in the treatment of rheumatoid arthritis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 116-120.

参考文献

[1] 王永福. 糖皮质激素对类风湿关节炎治疗作用的再认识[J]. 中国处方药,2008,7(9):65-67.
[2] Van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis:clinical efficacy, disease-modifying properties, and side effects:a randomized, double-blind, placebo-controlled clinical trial[J]. Ann Intern Med, 2002, 136(1): 1-12.
[3] Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial [J]. Ann Intern Med, 2007, 146(6): 406-415.
[4] Machold KP,Landewe R,Smolen JS, et al. The Stop Arthritis Very Early (SAVE)trial, an international multicentre, randomised, double-blind, placebo-control-led trial on glucocorticoids in very early arthritis[J].Ann Rheum Dis,2010,69(3): 495-502.
[5] Todoerti M, Scire CA, Boffini N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis[J]. Ann NY Acad Sci,2010, 1193: 139-145.
[6] Ciconelli RM, Ferraz MB, Santos W, et al. Traducao para a lingua portuguesa e validacao do questionario generico de avaliacao de qualidade de vida SF-36 (Brasil SF-36)[J]. Rev Bras Reumatol, 1999, 39: 143-150.
[7] Choy EHS, Scott DL. Drug treatment of rheumatic diseases in the 1990s[J]. Drugs, 1997, 53(3): 337-348.
[8] Hansen M,Podenphant J,Florescu A,et al.A randomized trial of differentiated prednisolone treatment in active rheumatoid arthritis:clinical benefits and skeletal side effects[J].Ann Rheum Dis,1999,58(11):713-718.
[9] Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment[J]. Ann Rheum Dis, 2004,63(9): 1069-1074.
[10] 李征寒,吴东红,王丽娟. 联合小剂量糖皮质激素治疗类风湿关节炎临床研究[J]. 中国现代药物应用,2009, 7(13):132-133.
[11] 徐胜前,邵宜波,徐建华,等. 类风湿关节炎患者骨密度变化的临床研究[J]. 临床内科杂志, 2004, 21(11): 763-765.
[12] Vosse D, de Vlam K. Osteoporosis in rheumatoid arthritis and ankylosing spondylitis[J]. Clin Exp Rheumatol, 2009, 27(4): S62-S67.
[13] 何伟珍,李剑松,李博, 等. 绝经前女性风湿病患者骨密度变化影响因素分析[J].实用医学杂志,2009,25(7):394-396.
[14] 张江林. 类风湿关节炎的骨质疏松研究进展[J]. 中华风湿病学杂志, 2008, 8(3): 503-505.
[15] Reid IR, Grey AB. Corticosteroid osteoporosis[J]. Bailliere's Clin Rheumatol, 1993, 7(7): 573-587.
[16] Baltzan MA, Suissa S, Bauer DC, et al. Hip fractures attributable to corticosteroid use[J]. Lancet, 1999, 353(9161): 1327.
[17] Wang JJ,Hu B,Kong LT,et al.Native,oxidized lipoprotein(a) and 1ipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis:Plasma concentrations and relationship to inflammation[J]. Clin Chim Acta,2008,390(1/2):67-71.
[18] 胡兵,汪俊军,张春妮,等.类风湿关节炎患者丙二醛修饰低密度脂蛋白及低密度脂蛋白循环免疫复合物水平分析[J].中国动脉硬化杂志,2008,16(7):296-298.
[19] Cannen GG,Joan MN,Josep V,et al.Conventional lipid profile and lipopr otein(a)concentrations in treated patiens with rheumatoid arthritis [J]. J Rheumtol,2009,36(121):1365-1370.
[20] Gomez CG,Nolla JM,Valverde J,et al.High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucoeorticoid therapy[J].Eur J Ctin Invest,2008,38(33):686-692.
[21] 林小军,李伟念,何志翔,等. 小剂量糖皮质激素对类风湿关节炎患者血脂水平的影响[J]. 中国现代医生,2010, 7(6):11-12.
[22] Yong BP,Hyon,KC,Min YK,et al.Effects of antirheumtic therapy on serum lipid levels in patients with rheumatoid arthritis:a prospective study[J].Am J Med,2002,113(6):188-193.
[23] Somers EC,Thomas SL,Smeeth L,et al.Autoirmnune diseases co-occurring within individuals and within families:a systematic review[J]. Epidemiology, 2006,17(3):202-205.
[24] Liao KP,Gunnarsson M,Kllberg H,et al.Specific association of type 1 diabetes mellitus with anticyclic citrullinated peptide-positive rheumatoid arthritis[J].Arthritis Rheum,2009,60(6):653-657.
[25] Toms TE,Panoulas VF,John H,et al.Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60-more than just an anti- inflammatory effect? A cross sectional study[J].Arthritis Res Ther,2009, 11(4):R110.
[26] Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future[J] ? Arthritis Rheum,2002, 46(10): 2552-2563

糖皮质激素在类风湿关节炎中的应用进展

Advances of study on glucocorticoids in the treatment of rheumatoid arthritis

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	范杰, 金永明, 江孝龙, 蒋国华. lncRNA HOTAIR调控miR-206影响类风湿关节炎滑膜细胞增殖和凋亡的分子机制研究[J]. 中国临床药理学与治疗学, 2023, 28(7): 736-742.
[7]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[8]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[9]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[10]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[11]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[12]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[13]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[14]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[15]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.